Nanobiotix (5NR F) stock market data APIs
€3.1885
-0.09(-2.7%)
as of March 26, 2025
Nanobiotix Financial Data Overview
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Prev. Close
3.2813
Open
3.1885
High
3.2813
Low
3.1885
52 wk Range
2.65-6.8
Market Cap
158 M
Shares Outstanding
47 405 K
Revenue
42 204 K
EPS
0
Beta
1.38
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nanobiotix data using free add-ons & libraries
Get Nanobiotix Fundamental Data
Nanobiotix Fundamental data includes:
- Net Revenue: 42 204 K
- EBITDA: -22 295 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-22
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nanobiotix News
New
Baillie Gifford Bolsters Stake in Nanobiotix SA
Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently increased its investment in Nanobiotix SA, a company at the forefront of nanotechnology in cancer treatment. ...
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix S.A. PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company...
Voting Rights and Shares Capital of the Company
Nanobiotix S.A. InaccordancewithArticlesL.233-8II oftheFrenchCommercial Codeand223-16ofthe General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan...
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
Nanobiotix S.A. PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
